Tagged with R&D

Korea From Wednesday 31st October to Friday 2nd November, Seoul hosted the KoNECT-MFDS International conference, promoting South Korea’s clinical research capabilities on a global platform. The fourth of its kind, the conference was based around the main theme of embracing change in clinical research. The conference was organised by KoNECT –…

Korea Korea is fast becoming a big player in the pharmaceutical industry, especially within the biotech arena. With 4% of the total pipelines in the world, the country is showing strong R&D capabilities and fierce ambitions for growth. Korea is now the 3rd largest pharma region in Asia, with a forecasted…

Turkey Maria Fernanda Prado, managing director of Janssen Turkey, elaborates on the unique dynamics at play in Turkey; an important emerging market. Prado addresses the challenges, advantages, and opportunities that exist in the market and speaks to the dedication Janssen has placed into the vibrant country. From my experience in Brazil,…

Korea Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment of acute myeloid leukaemia (AML).   The endorsement of FDA’s Orphan Drug Designation (ODD) — invented to smooth the development of therapies for life-threatening…

France Ipsen CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come.   From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…

France Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…

Spain Francesc Posas, the newly appointed director of the Institute for Research in Biomedicine (IRB Barcelona), explains the evolving role of the institute as a bridge between basic research and concrete patient treatments.  I would like the world to know that there is a lot of outstanding science being done in…

France Genethon, a laboratory created by the patient organization AFM-Telethon, is one of the world’s leaders in the development of biotherapies for rare diseases. In this interview Genethon’s CEO Frédéric Revah explains its role in the discovery of innovative therapies since the 1990s and the recent launch of YposKesi, its innovative…

China Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry.   Napoleon once said: “China is a sleeping giant. Let her sleep, for when she wakes she will shake the world.” Well, in biotech, she is now wide awake I’ve recently returned from…

France Prof. Stanislas Lyonnet, director of the Imagine Institute in Paris, France, explains his organization’s unique ecosystem that brings together researchers, physicians, patients and private actors to find the cure to genetic diseases.   Could you please introduce yourself and tell us why you decided to take the helm of the…

Algeria Radwa Terbeche, general manager of Amgen in Algeria discusses the potential for biosimilars in Algeria and the company’s role in developing a local clinical research infrastructure.   What has been your journey to becoming country manager of Amgen Algeria? By education I am a pharmacist specialized in industry. After graduating,…

R&D In my career, I’ve held senior roles in both the biopharma and diagnostics sectors. Working across different cost structures, different business issues, and different regulatory systems in different parts of the world. I was once challenged as a new CEO in diagnostics by a pharma analyst to explain why I…